ReShape Lifesciences Inc Total Assets
ReShape Lifesciences Inc total assets. Based on the latest financial reports, ReShape Lifesciences Inc (RSLS) holds total assets worth $9.03 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see RSLS stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of ReShape Lifesciences Inc (2003–2024)
Total assets of ReShape Lifesciences Inc from 2003 to 2024. This chart illustrates how ReShape Lifesciences Inc's total assets have evolved over time, based on quarterly financial data. See ReShape Lifesciences Inc (RSLS) share price today for real-time trading data and today's change.
ReShape Lifesciences Inc - Asset Composition Analysis
ReShape Lifesciences Inc Total Assets Breakdown (December 2024)
ReShape Lifesciences Inc total assets breakdown as of December 2024. ReShape Lifesciences Inc's total assets of $9.03 Million consist of 95.7% current assets and 4.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.5% |
| Accounts Receivable | $987.00K | 20.6% |
| Inventory | $2.46 Million | 51.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how ReShape Lifesciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore RSLS current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ReShape Lifesciences Inc's current assets represent 95.7% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 14.5% of total assets in 2024, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is inventory at 51.3% of total assets.
ReShape Lifesciences Inc Competitors by Total Assets
Key competitors of ReShape Lifesciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥916.43 Million |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.57 Billion |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
|
Pulsenmore Ltd
TA:PULS
|
Israel | ILA120.34 Million |
|
Adherium Ltd
AU:ADR
|
Australia | AU$4.16 Million |
ReShape Lifesciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.77 | 1.90 | 0.57 |
| Quick Ratio | 1.97 | 0.89 | 0.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.66 Million | $2.89 Million | $-6.12 Million |
ReShape Lifesciences Inc - Advanced Valuation Insights
This section examines the relationship between ReShape Lifesciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 30.42 |
| Latest Market Cap to Assets Ratio | 1.95 |
| Asset Growth Rate (YoY) | -55.1% |
| Total Assets | $4.79 Million |
| Market Capitalization | $9.35 Million USD |
Valuation Analysis
Above Book Valuation: The market values ReShape Lifesciences Inc's assets above their book value (1.95x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: ReShape Lifesciences Inc's assets decreased by 55.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ReShape Lifesciences Inc (2003–2024)
The table below shows the annual total assets of ReShape Lifesciences Inc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.79 Million | -55.05% |
| 2023-12-31 | $10.66 Million | -4.30% |
| 2022-12-31 | $11.14 Million | -79.46% |
| 2021-12-31 | $54.26 Million | +46.40% |
| 2020-12-31 | $37.06 Million | -6.54% |
| 2019-12-31 | $39.66 Million | -14.30% |
| 2018-12-31 | $46.27 Million | -47.84% |
| 2017-12-31 | $88.70 Million | +1159.84% |
| 2016-12-31 | $7.04 Million | -39.23% |
| 2015-12-31 | $11.59 Million | -19.46% |
| 2014-12-31 | $14.39 Million | -45.48% |
| 2013-12-31 | $26.39 Million | +1.12% |
| 2012-12-31 | $26.10 Million | -19.67% |
| 2011-12-31 | $32.49 Million | -16.03% |
| 2010-12-31 | $38.69 Million | +138.60% |
| 2009-12-31 | $16.21 Million | -42.66% |
| 2008-12-31 | $28.28 Million | -52.11% |
| 2007-12-31 | $59.05 Million | +63.74% |
| 2006-12-31 | $36.06 Million | +211.95% |
| 2005-12-31 | $11.56 Million | +1512.39% |
| 2003-12-31 | $717.00K | -- |
About ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more